Wolverine Asset Management LLC Nrx Pharmaceuticals, Inc. Transaction History

Wolverine Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.23 - $0.5 $175 - $381	-763 Reduced 7.33%	9,644 $2,000
Q2 2023 Aug 07, 2023	SELL	$0.46 - $0.89 $337 - $653	-734 Reduced 6.59%	10,407 $4,000
Q1 2023 May 08, 2023	SELL	$0.66 - $1.4 $3,092 - $6,560	-4,686 Reduced 29.61%	11,141 $7,000
Q4 2022 Feb 01, 2023	SELL	$0.79 - $9.19 $6,672 - $77,618	-8,446 Reduced 34.8%	15,827 $17,000
Q3 2022 Nov 10, 2022	SELL	$0.2 - $8.07 $748 - $30,181	-3,740 Reduced 13.35%	24,273 $17,000
Q2 2022 Aug 03, 2022	SELL	$0.51 - $2.42 $3,251 - $15,427	-6,375 Reduced 18.54%	28,013 $16,000
Q1 2022 May 04, 2022	SELL	$2.45 - $5.04 $6,656 - $13,693	-2,717 Reduced 7.32%	34,388 $84,000
Q4 2021 Feb 09, 2022	SELL	$4.5 - $11.91 $24,583 - $65,064	-5,463 Reduced 12.83%	37,105 $177,000
Q3 2021 Nov 12, 2021	BUY	$8.52 - $24.77 $196,624 - $571,642	23,078 Added 118.41%	42,568 $394,000
Q2 2021 Aug 13, 2021	BUY	$11.62 - $44.5 $226,473 - $867,305	19,490 New	19,490 $226,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $111M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.